TY - JOUR
T1 - Myeloma
T2 - Classification and risk assessment
AU - Fonseca, Rafael
AU - Monge, Jorge
PY - 2013/10
Y1 - 2013/10
N2 - Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a detailed classification of the disease into at least seven or eight major subtypes is possible, a practical clinical approach classifies the disease into high-risk and not-high-risk MM. This classification has allowed for tailored approaches to therapy and treatment planning. Furthermore, the discussion of outcomes with patients should include risk stratification, as the prospects for survival are quite different depending on whether the patient has high-risk MM or not. The tools for measuring risk subcategory are widely available and now routinely employed in the clinic. The continued search for genetic abnormalities that underlie the biology of MM may allow for even better precision therapy in the future.
AB - Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a detailed classification of the disease into at least seven or eight major subtypes is possible, a practical clinical approach classifies the disease into high-risk and not-high-risk MM. This classification has allowed for tailored approaches to therapy and treatment planning. Furthermore, the discussion of outcomes with patients should include risk stratification, as the prospects for survival are quite different depending on whether the patient has high-risk MM or not. The tools for measuring risk subcategory are widely available and now routinely employed in the clinic. The continued search for genetic abnormalities that underlie the biology of MM may allow for even better precision therapy in the future.
UR - http://www.scopus.com/inward/record.url?scp=84886891720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886891720&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2013.07.002
DO - 10.1053/j.seminoncol.2013.07.002
M3 - Article
C2 - 24135400
AN - SCOPUS:84886891720
SN - 0093-7754
VL - 40
SP - 554
EP - 566
JO - Seminars in oncology
JF - Seminars in oncology
IS - 5
ER -